RxDoctor Payments Data

Christopher Rodarte, MD

Family Medicine · Visalia, CANPI 1053383091

Payments from drug & device makers

$9,806in general payments, 2019–2025

Across 548 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Boehringer Ingelheim$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$794
  • Amgen$616
  • Novo Nordisk$536
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$9,69299%
  • Education$1141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,806 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$155,434
Medicare patients
269
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin168$224,260
OzempicSemaglutide129$177,747
ZenpepLipase/Protease/Amylase19$120,662
EliquisApixaban82$83,210
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$43,840
FarxigaDapagliflozin Propanediol30$41,395
VraylarCariprazine Hcl21$39,839
RybelsusSemaglutide21$37,952
LinzessLinaclotide35$30,852
TrulicityDulaglutide19$25,687
MyrbetriqMirabegron30$22,704
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen305$9,017
Breo ElliptaFluticasone/Vilanterol21$8,938
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$7,746
Novolog FlexpenInsulin Aspart21$6,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,091$224,260168 claims
Novo NordiskOzempic, Rybelsus$536$215,699150 claims
Aimmune Therapeutics, Inc.Zenpep$17$120,66219 claims
PfizerEliquis, Paxlovid$343$84,639101 claims
AbbVieVraylar, Linzess$1,601$70,69156 claims
GSKTrelegy Ellipta, Breo Ellipta$168$52,77850 claims
AstraZenecaFarxiga$1,022$41,39530 claims
Lilly USA, LLCTrulicity$794$25,68719 claims
Astellas Pharma US IncMyrbetriq$96$22,70430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →